The Lancet. Public health
-
The Lancet. Public health · Dec 2019
Italy's health performance, 1990-2017: findings from the Global Burden of Disease Study 2017.
Through a comprehensive analysis of Italy's estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we aimed to understand the patterns of health loss and response of the health-care system, and offer evidence-based policy indications in light of the demographic transition and government health spending in the country. ⋯ Bill & Melinda Gates Foundation.
-
The Lancet. Public health · Aug 2019
20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study.
Heart failure is an important public health issue affecting about 1 million people in the UK, but contemporary trends in cause-specific outcomes among different population groups are unknown. ⋯ Wellcome Trust.
-
The Lancet. Public health · Jun 2019
Comparative StudyGeospatial, racial, and educational variation in firearm mortality in the USA, Mexico, Brazil, and Colombia, 1990-2015: a comparative analysis of vital statistics data.
Firearm mortality is a leading, and largely avoidable, cause of death in the USA, Mexico, Brazil, and Colombia. We aimed to assess the changes over time and demographic determinants of firearm deaths in these four countries between 1990 and 2015. ⋯ Canadian Institutes of Health Research and the University of Toronto Connaught Global Challenge.
-
The Lancet. Public health · Jan 2019
Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women Study.
Alcohol is a known cause of cirrhosis, but it is unclear if the associated risk varies by whether alcohol is drunk with meals, or by the frequency or type of alcohol consumed. Here we aim to investigate the associations between alcohol consumption with meals, daily frequency of consumption, and liver cirrhosis. ⋯ UK Medical Research Council and Cancer Research UK.
-
The Lancet. Public health · Jan 2019
The projected timeframe until cervical cancer elimination in Australia: a modelling study.
In 2007, Australia was one of the first countries to introduce a national human papillomavirus (HPV) vaccination programme, and it has since achieved high vaccination coverage across both sexes. In December, 2017, organised cervical screening in Australia transitioned from cytology-based screening every 2 years for women aged from 18-20 years to 69 years, to primary HPV testing every 5 years for women aged 25-69 years and exit testing for women aged 70-74 years. We aimed to identify the earliest years in which the annual age-standardised incidence of cervical cancer in Australia (which is currently seven cases per 100 000 women) could decrease below two annual thresholds that could be considered to be potential elimination thresholds: a rare cancer threshold (six new cases per 100 000 women) or a lower threshold (four new cases per 100 000 women), since Australia is likely to be one of the first countries to reach these benchmarks. ⋯ National Health and Medical Research Council (Australia).